Roquefort Therapeutics (LON:ROQ) Shares Down 10.5% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) shares fell 10.5% on Wednesday . The company traded as low as GBX 2.32 ($0.03) and last traded at GBX 2.33 ($0.03). 1,770,633 shares traded hands during mid-day trading, a decline of 13% from the average session volume of 2,032,882 shares. The stock had previously closed at GBX 2.60 ($0.03).

Roquefort Therapeutics Stock Down 2.0 %

The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The firm has a fifty day simple moving average of GBX 3.84 and a 200-day simple moving average of GBX 3.93. The firm has a market cap of £2.97 million, a price-to-earnings ratio of -230.20 and a beta of 0.05.

Insider Transactions at Roquefort Therapeutics

In other news, insider Stephen Paul West bought 400,000 shares of the stock in a transaction dated Tuesday, February 4th. The shares were bought at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($14,942.10). 60.40% of the stock is currently owned by corporate insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.